Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genfit SA ( (GNFT) ) has issued an announcement.
On February 10, 2025, GENFIT announced the final terms for a dual proposal to its 2025 OCEANEs bondholders, in conjunction with a previously announced royalty financing agreement with HealthCare Royalty. The company proposes to repurchase the bonds at EUR 32.00 each or pay a consent fee of EUR 0.60 per bond if repurchased. This is contingent upon the bondholders approving an amendment to the terms and the closing of the royalty financing. The deal is expected to significantly extend GENFIT’s cash runway and impact its financial stability positively, pending bondholder approval at a forthcoming meeting.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. With over two decades of experience, GENFIT has a diverse portfolio of research and development programs aimed at addressing conditions like Acute-on-Chronic Liver Failure (ACLF), cholangiocarcinoma (CCA), urea cycle disorder (UCD), and organic acidemia (OA). The company is also involved in diagnostics, exemplified by their NIS2+® test for Metabolic dysfunction-associated steatohepatitis (MASH). Headquartered in Lille, France, GENFIT operates in multiple locations, including Paris, Zurich, and Cambridge, MA, and is listed on Nasdaq and Euronext.
YTD Price Performance: 2.09%
Average Trading Volume: 8,221
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $192.7M
See more data about GNFT stock on TipRanks’ Stock Analysis page.
